News · 26 weeks53+60%
2025-12-282026-06-21
Mix3690d
- Other15(42%)
- Insider13(36%)
- SEC Filings5(14%)
- Leadership2(6%)
- Market1(3%)
Latest news
25 items- INSIDERChief Strategy Officer Bond Ryan was granted 55,000 shares (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERExecutive Chairman Thramann Jeffrey John was granted 100,000 shares (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERChief Financial Officer Gould Gregory A was granted 50,000 shares (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERDirector Sequira Amanda Mae was granted 20,000 shares (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERDirector Breidbart Scott was granted 20,000 shares, increasing direct ownership by 353% to 25,664 units (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERDirector Wesemann William was granted 20,000 shares, increasing direct ownership by 1,280% to 21,563 units (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERDirector Deitsch Stephen was granted 20,000 shares (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERDirector Neal David K was granted 20,000 shares, increasing direct ownership by 799% to 22,502 units (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERChief Executive Officer Ness Brent was granted 100,000 shares, increasing direct ownership by 1,587% to 106,300 units (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- PRAclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClubBROOMFIELD, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today announced that it will be presenting at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub on Wednesday, June 17, 2026 at 8:30 AM PT at the Bellagio Resort & Hotel. Jeff Thramann, Executive Chairman, will be hosting the presentation and answering questions at the conclusion. Recent Key Highl
- PRAclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan PlatformPartnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven platform for chronic low back pain. Program aims to follow successful reimbursement wins in the UK that are translating into sustained scan volume growth in step with reduced market access barriers BROOMFIELD, Colo., June 09, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the launch of a Market Access Program in partnership with PRIA Heal
- PRAclarion Rejects Echo Lake Capital's Unsolicited Acquisition ProposalBROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today issued the following statement in response to a recent communication issued by Echo Lake Capital and its principal, Ephraim Fields. Aclarion's Board of Directors carefully reviewed Echo Lake's unsolicited public proposal and unanimously determined to reject it. The Board believes that the proposal significantly undervalues the Company and its strategic potential. Th
- PRAclarion Stockholders Approve All Proposals at 2026 Annual MeetingBROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that its stockholders approved all proposals at its 2026 Annual Meeting of Stockholders held on June 4, 2026. The approved proposals included the election of Jeffrey Thramann, Brent Ness, Stephen Deitsch, Scott Breidbart, David Neal, William Wesemann, and Amanda Williams to the Board of Directors to serve until the 2027 annual meeting, the ratification of
- SECAclarion Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Aclarion, Inc. (0001635077) (Filer)
- PRAclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence GenerationExpands availability of Nociscan in the greater Los Angeles area with leading neuroscience groupAdds to growing body of real-world evidence with study comparing chemical biomarker data from Nociscan with bone metabolic information from SPECT-CT Supports scalable growth strategy while building data assets critical to payer and provider adoption BROOMFIELD, Colo., June 03, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pai
- PRAclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker StudyAward-winning, NIH funded study indicates that immune-associated biological signatures may play a role in some cases of back painNociscan's underlying MRS technology enabled measurement of intradiscal propionic acid to uncover immune-linked patient subtypesLatest findings point to potential clinical applications of Nociscan beyond surgical decision support, expanding the future scope of precision spine care BROOMFIELD, Colo., June 01, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify
- PRAclarion, Inc. Comments on Echo Lake Capital's Letter and Unsolicited ProposalBROOMFIELD, Colo., May 28, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today issued the following statement in response to the press release issued by Echo Lake Capital and its offer to acquire the Company for $4.00 per share in cash and contingent value rights: Aclarion's Board of Directors and management team are committed to acting in the best interests of the Company and all of its shareholders. We regularly review our strategic priorities and evaluate op
- NEWSEcho Lake Capital Offers To Acquire Aclarion Inc.Offers $4.00 per share in cash plus CVRStock currently trades below the value of its cash and other assetsBelieves company's public shell worth at least another $6 million if Board effected a reverse takeoverStock price down 99% since its IPO only four years agoBoard owns few shares so lacks financial incentive to maximize shareholder valueDirectors have been paid $5.6 million or 50% of company's current equity market valueThramann has overseen destruction of shareholder value at Aclarion and Auddia Inc. with both stocks down 99% since their IPOs"Independent" Director Deitsch has been sued for violating securities law and has longstanding relationship with ThramannBelieves certain directors
- SECSEC Form 10-Q filed by Aclarion Inc.10-Q - Aclarion, Inc. (0001635077) (Filer)
- INSIDERDirector Breidbart Scott bought $18,012 worth of shares (5,664 units at $3.18) (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERDirector Neal David K bought $7,750 worth of shares (2,500 units at $3.10), increasing direct ownership by 125,000% to 2,502 units (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERChief Executive Officer Ness Brent bought $19,999 worth of shares (6,289 units at $3.18), increasing direct ownership by 57,173% to 6,300 units (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERDirector Wesemann William bought $5,155 worth of shares (1,562 units at $3.30), increasing direct ownership by 156,200% to 1,563 units (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- PRAclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment"Matching the right procedure to the right patient is what moves the field forward" Lanman Spinal Neurosurgery is a leading spine-focused private practice recognized for its expertise in complex spinal procedures, early adoption of innovative technologies and high surgical volumeThe CLARITY randomized clinical trial is designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain BROOMFIELD, Colo., May 07, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the locati
- PRAclarion Announces Inducement Grant to New Commercial Director, Western U.S.BROOMFIELD, Colo., May 06, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today announced that the compensation committee of Aclarion's board of directors granted Daniel Keefe, the Company's recently-hired Commercial Director, Western U.S., an inducement stock option to purchase an aggregate of 17,000 shares of Aclarion's common stock on May 5, 2026. This stock option was
ACON FAQ
6 questionsWhat does Aclarion Inc. do?
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.Where does ACON stock trade?
Aclarion Inc. (ACON) is listed on NASDAQ.What sector and industry is ACON in?
Aclarion Inc. operates in the Health Care sector, Medical Specialities industry.When did Aclarion Inc. go public?
Aclarion Inc. (ACON) completed its IPO in 2022.What companies are similar to ACON?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare ACON side-by-side with any of them on Quantisnow.How can I track ACON on Quantisnow?
Quantisnow aggregates Aclarion Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACON to receive live email and push alerts on every new disclosure.